Ever Supreme Bio Technology announced consolidated revenue of NT$72.46 million for May, representing a 7.28% month-on-month increase and a 20.53% year-on-year growth, setting a new record high for the same period. Cumulative revenue for the first five months of the year reached NT$318 million, up 13.7% compared to the previous year. The company attributed the revenue momentum in May mainly to steady growth in its cell therapy CDMO (contract development and manufacturing organization) services and cell storage business.

In new drug development, Ever Supreme’s flagship product, the allogeneic mRNA CAR-T therapy CAR001 targeting solid tumors, has completed patient enrollment for the third dosing cohort (Cohort 3), with a total of nine subjects to date. No severe adverse events such as cytokine release syndrome (CRS), graft-versus-host disease (GvHD), or neurotoxicity have been reported, indicating good tolerability of the therapy. The clinical trial is currently progressing with dose escalation toward the maximum tolerated dose (MTD). The company is also actively negotiating technology licensing and strategic partnerships with international pharmaceutical companies to enhance the global development and commercialization potential of CAR001.

Liu Zhu-qi stated that 2025 is a critical year for Ever Supreme’s international expansion. The company will continue to strengthen its CDMO service capabilities and accelerate clinical trials of CAR001 in both the U.S. and Taiwan. Combining stable profitability with international licensing potential, Ever Supreme aims to lay a solid foundation for medium- to long-term operational growth, while maintaining a stable dividend policy to fulfill its dual value commitment to shareholders and society.

Resource: 長聖5月營收續創同期新高 兩大業務穩定成長